ANTWERP, Belgium, Oct. 3, 2024 /PRNewswire/ -- At the
43rd Congress of the European Society of Surgical
Oncology (ESSO), three leading breast surgeons presented data
demonstrating the clinical benefits of The MOZART® 3D
Specimen Radiography System from KUBTEC®.
Dr. Ash Kothari (Guy's Hospital, UK), Dr. Tomasz Sachańbiński
(Opole Oncology Center, Poland),
and MUDr. Jan Beneš (České Budějovice Hospital, Czech Republic) each shared data from their
respective institutions, all pointing to a consistent trend: use of
The MOZART System can significantly reduce the need for re-excision
surgeries for breast cancer patients. MUDr. Jan Beneš also
presented data on how The MOZART System has enabled more healthy
tissue preservation at his facility – an important factor in
improving patient post-operative cosmesis.
"The MOZART System with its tomosynthesis imaging technology
gives us immediate and highly detailed 3D information, which allows
us to make more precise surgical decisions," remarked Dr. Kothari.
"Reducing repeat surgeries is a huge benefit for patients and
healthcare systems."
Data presented at the symposium reinforced prior clinical
findings from the US, where The MOZART System has been a valuable
tool for intraoperative margin assessment for several years.
Multiple studies have shown that the system not only facilitates a
reduction in re-excision rates, but can also lead to better patient
cosmesis and overall surgical efficiency*
Richard Whelton, Head of
Marketing at KUBTEC said, "We are thrilled to see this data coming
from Europe, but it is not a
surprise. At KUBTEC, we believe The MOZART System should become
part of the standard of care for margin management. We'll be
calling on more breast surgeons globally to contribute their data,
so that together we can shape the future of breast surgery."
*For more information about The MOZART System, including details
on previous studies, please visit www.kubtec.com. A recording of
the symposium presentations will be available on the website.
About KUBTEC:
KUBTEC is a family-owned medical technology company, headquartered
in Connecticut, USA. Our passion
is developing transformative technologies that enable precision
surgery for breast cancer, leading to improved patient outcomes and
quality of care. For nearly 20 years, we have led the way in
specimen imaging across the Operating Room, Pathology Lab and
Biopsy Suite. Building on this legacy, we also now provide an
innovative gamma probe detection system that seamlessly integrates
with our imaging solutions.
Logo -
https://mma.prnewswire.com/media/2194547/MicrosoftTeams_image__10_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/new-data-indicates-use-of-3d-specimen-tomosynthesis-can-improve-breast-cancer-surgical-outcomes-302265841.html